Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Apply “Game Theory” to Cancer Research

July 16, 2014 10:47 am | News | Comments

Cancer’s no game, but researchers at Johns Hopkins are borrowing ideas from evolutionary game theory to learn how cells cooperate within a tumor to gather energy, so that they can identify the ideal time to disrupt metastatic cancer cell cooperation and make a tumor more vulnerable to anti-cancer drugs. Read more...

TOPICS:

Abbott 2Q Revenue Up

July 16, 2014 10:25 am | by The Associated Press | News | Comments

Abbott Laboratories (ABT) said Wednesday that its second-quarter profit declined 2.1%, hampered by higher taxes. Adjusted profit and revenue topped Wall Street expectations, however, and the company boosted its full-year earnings forecast. Read more...

TOPICS:

Avastin Gets Priority Review for Certain Types of Cervical Cancer

July 15, 2014 3:12 pm | News | Comments

Genentech announced that the FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer. Read more...

TOPICS:
Advertisement

Tamoxifen Gel Effective When Applied to Breast

July 15, 2014 3:08 pm | News | Comments

A breakdown product of tamoxifen, 4-OHT, applied as a gel formulation on the breasts of women with ductal carcinoma in situ (DCIS), was as effective in reducing cell proliferation as oral tamoxifen, with fewer side effects compared with oral tamoxifen, according to a study. Read more...

TOPICS:

FDA Grants Priority Review to New Hep C Combo

July 15, 2014 2:51 pm | News | Comments

Medivir AB announced that the FDA has assigned a Priority Review designation to the supplemental New Drug Application for the use of once-daily Olysio, in combination with sofosbuvir, for 12 weeks treatment of adult patients with genotype 1 chronic hepatitis C. Read more...

TOPICS:

Researchers Alleviate Pulmonary Inflammation Through Targeted Drug Delivery

July 15, 2014 2:43 pm | News | Comments

To date, no medication has been successful at preventing or mitigating the damage caused by pulmonary inflammation. Now, a research team has found that when delivered by a microscopic transporter called a nanocarrier, steroids can access the hard-to-reach lung endothelial cells that need it most and are successful at preventing inflammation in mice. Read more...

TOPICS:

Novartis to Use Google Technology for 'Smart' Contacts

July 15, 2014 2:19 pm | News | Comments

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease. Read more...                 

TOPICS:

Codexis, GSK Collaborate on Platform Technology

July 15, 2014 11:38 am | News | Comments

Codexis Inc., a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announced the signing of a platform technology license agreement with GlaxoSmithKline under which Codexis granted GSK a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. Read more...

TOPICS:
Advertisement

Cognitive Impairment Precedes, Predicts Alzheimer's Functional Impairment

July 15, 2014 11:29 am | News | Comments

Eli Lilly announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease, which suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. Read more...

TOPICS:

Pradaxa Available in the UK for DVT, PE

July 15, 2014 11:23 am | News | Comments

Boehringer Ingelheim has announced that Pradaxa will be commercially available in the UK for the treatment of DVT and PE - dangerous conditions with over 25,000 deaths estimated to occur in hospitalized patients each year in the UK - and the prevention of recurrent DVT and PE in adults, from Tuesday. Read more...

TOPICS:

Centralized Data Management Improves Collaboration

July 15, 2014 11:16 am | by Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS | Articles | Comments

Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...

TOPICS:

U.S. Drug Companies Look Overseas for Tax Relief

July 15, 2014 11:02 am | by Tom Murphy, AP Business Writer | News | Comments

A growing number of U.S. companies are looking to trim their tax bills by combining operations with foreign businesses in a trend that may eventually cost the federal government billions of dollars in revenue. For example, generic drugmaker Mylan Inc. said Monday it will become part of a new company organized in the Netherlands. Read more...

TOPICS:

Worldwide Alzheimer's, Dementia Epidemic Grows

July 15, 2014 10:54 am | News | Comments

While the global epidemic of Alzheimer's disease continues to grow, new data on lower incidence in the "youngest old" from developed countries in Europe and the United States suggest the possibility of reducing risk and/or preventing the disease, according to the results of research studies announced at the Alzheimer's Association International Conference 2014. Read more...

TOPICS:

Hepatitis Drug Boosts J&J Profits in Q2

July 15, 2014 9:23 am | by Linda A. Johnson, AP Business Writer | News | Comments

Strong sales of several new drugs, particularly its hot new hepatitis medicine, lifted Johnson & Johnson's second-quarter profit by 13%, topping analysts' expectations. Read more...                    

TOPICS:

Cannabis Compound Could Slow Tumor Growth, Research Shows

July 14, 2014 2:26 pm | News | Comments

Scientists have shown how the main psychoactive ingredient in cannabis could reduce tumor growth in cancer patients. Read more...                                   

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading